Quick Menu

Upcoming Journals

Journal of Pharmaceutical Research International

Journal of Pharmaceutical Research International, ISSN: 2456-9119, ISSN: 2231-2919 (past),Vol.: 23, Issue.: 4

Review Article

Chimeric Antigen Receptor T Cell (CAR – T) Therapy – A Novel Treatment in Cancer

 

Priyadarsini Baskaran1*, Venkatraman Karthikeayan2 and Anusha Natarajan1

1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.

2Gleneagles Global Hospital, Chennai, Tamil Nadu, India.

 

Article Information

Editor(s):

(1) Dr. Rahul S. Khupse, Pharmaceutical Sciences, University of Findlay, USA.

Reviewers:

(1) Lívia Garcia Bertolacci-Rocha, Universidade Federal de Goiás, Brasil.

(2) Thompson Akinbolaji, Yuma Regional Medical Center, USA.

(3) Poggi Alessandro, IRCCS AOU San Martino, Italy.

(4) Pratibha Kamble, University of Mumbai, India.

(5) Wagih Mommtaz Ghannam, Mansoura University, Egypt.

Complete Peer review History: http://www.sciencedomain.org/review-history/26188

 

Abstracts

 

Cancer is one of the most challenging diseases affecting mankind. It continues to defy all the treatment modalities and advancements and claims millions of lives every year. Chimeric Antigen Receptor –T (CAR-T) cell therapy is one of the breakthroughs in cancer treatment. Chimeric antigen receptor is a recombinant immunoreceptor that enables the T cells to recognise and kill tumour surface antigens in a non MHC (Major Histocompatibility Complex) restricted manner. There are four generations of CAR-T cells, of which the second generation CAR-T cells have maximum efficacy clinically. In 2017, two CAR-T cell therapies were approved by FDA for the treatment of ALL (Acute Lymphoblastic Leukaemia) and NHL (Non-Hodgkin's Lymphoma). More than 80% remission is achieved with these tumours which are resistant to all other treatment modalities. Now CAR-T cell therapies are being tested for non – haematological malignancies also. However, the adverse effects of CAR-T cell therapies are very severe like Cytokine Release syndrome (CRS) and on - target off - tumour toxicity. This review will attempt to cover the basic concept and the applications of CAR-T cells, their adverse effects, challenges faced and the future prospects of the CAR-T cells in treatment of cancer.

 

Keywords :

CAR-T therapy; chimeric antigen; anticancer agent.

 

Full Article - PDF    Page 1-11    Article Metrics

 

DOI : 10.9734/JPRI/2018/43471

Review History    Comments

Search this site

Advanced Search

Announcement & News

Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and its editors

We are happy to inform that Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and ...

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Science (IF: 31) report confirmed the high standard of SDI journal

As per a recent report (Link) of Science journal (present Impact factor 31), one of our journal (Bri...

SDI introduced Post-publication peer review by its comment section

SDI journals encourage Post-publication peer review by its comment section   Policy details a...

SDI promotes transparent Advanced OPEN peer review

We have migrated to transparent and toughest ‘Advanced OPEN peer review’ system (...



SCIENCEDOMAIN Awards

  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2018, SCIENCEDOMAIN international. All rights reserved.